News

According to Bloomberg, SpaceX perpetual futures accurately reflected market sentiment and converged to the stock trading range before the Nasdaq opened, but the SpaceX stock tokenization product was ultimately forced to refund as the trading platform failed to obtain enough underlying shares.

SK Hynix responded to Jiemian News stating that it is "exploring various options to enhance shareholder value, but the company has never discussed specific details such as the scale of shareholder returns mentioned in the relevant reports." Previously, The Korea Economic Daily reported that SK Hynix planned to launch an ultra-large shareholder return policy worth 100 trillion Korean won in the fourth quarter of this year, with specific measures including share buybacks and cash dividends. This move was interpreted by outsiders as a major strategic bet by SK Group Chairman Chey Tae-won, aiming to enhance the company’s position and valuation in the global capital market through large-scale shareholder returns.

These potential new products include a combined vaccine that protects against both influenza and COVID-19, an updated vaccine for seasonal influenza, and a new vaccine designed to prevent norovirus infection. This plan highlights Moderna’s ongoing expansion and in-depth application of its mRNA technology platform. The company is committed to extending its core mRNA research and development capabilities from the successful response to the COVID-19 pandemic to a broader range of respiratory and even gastrointestinal infectious diseases. If the combined influenza and COVID-19 vaccine is successfully launched, it could simplify public health immunization procedures and provide people with more convenient and comprehensive protection options. The development of a norovirus vaccine marks an important step for the company into a new field of disease prevention.Market analysts have pointed out that if this product pipeline plan progresses smoothly, it could open up new growth opportunities for Moderna in the coming years and strengthen its leading position in the global biotechnology and vaccine sectors. Investors are closely monitoring the progress of these research and development projects as well as their commercialization prospects.